TrialBlood cancer journal2015

Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies.

F Ravandi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.